Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[Use of rebiopsy for clinically diagnosed metastatic lesion in patients with breast cancer].

Qu Q, Xu C, Chen XS, Ren RB, Cai R, Lou GY, Shen KW.

Zhonghua Yi Xue Za Zhi. 2013 Sep 17;93(35):2820-2. Chinese.

PMID:
24360181
2.

The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer.

Qu Q, Zong Y, Fei XC, Chen XS, Xu C, Lou GY, Shen KW.

World J Surg Oncol. 2014 Apr 10;12:93. doi: 10.1186/1477-7819-12-93.

3.

[Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].

Wang B, Guan ZZ, Liu DG, Lin TY, Zhang L, Xia ZJ, Teng XY.

Ai Zheng. 2004 Dec;23(12):1710-3. Chinese.

PMID:
15601567
4.

Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.

Kos T, Aksoy S, Sendur MA, Arik Z, Civelek B, Kandemir N, Ozdemir NY, Zengin N, Altundag K.

J BUON. 2013 Jul-Sep;18(3):608-13.

PMID:
24065471
5.

Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.

Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.

J BUON. 2012 Apr-Jun;17(2):277-83.

PMID:
22740206
6.

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.

Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y.

Med Oncol. 2011 Mar;28(1):57-63. doi: 10.1007/s12032-010-9418-2. Epub 2010 Jan 23.

PMID:
20099049
7.

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.

J Clin Oncol. 2008 May 10;26(14):2373-8. doi: 10.1200/JCO.2007.14.4287. Epub 2008 Apr 14. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110.

PMID:
18413639
8.

Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.

Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, Massocco A, Manfrin E, Pegoraro C, Zamboni G.

Virchows Arch. 2011 Jul;459(1):1-10. doi: 10.1007/s00428-011-1097-7. Epub 2011 Jun 4.

9.

Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ.

Anticancer Res. 2009 May;29(5):1557-62.

10.

Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance.

Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, Wong NS, Tan PH.

Am J Clin Pathol. 2010 Mar;133(3):416-29. doi: 10.1309/AJCPJ57FLLJRXKPV.

PMID:
20154280
11.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
12.
13.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
14.

[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].

Li Q, Xu BH, Zhang P, Li Q, Yuan P, Wang JY, Luo Y, Ma F, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):207-11. doi: 10.3760/cma.j.issn.0253-3766.2013.03.010. Chinese.

PMID:
23880002
15.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.

Oncology. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.

PMID:
23257904
16.

Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre study.

Barinoff J, Hils R, Bender A, Groß J, Kurz C, Tauchert S, Mann E, Schwidde I, Ipsen B, Sawitzki K, Heitz F, Harter P, Traut A, du Bois A.

Eur J Cancer. 2013 Jan;49(2):305-11. doi: 10.1016/j.ejca.2012.07.027. Epub 2012 Aug 30.

PMID:
22940292
17.
18.

Estrogen and progesterone receptor concordance between primary and recurrent breast cancer.

Li BD, Byskosh A, Molteni A, Duda RB.

J Surg Oncol. 1994 Oct;57(2):71-7.

PMID:
7934066
19.

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.

de Dueñas EM, Hernández AL, Zotano AG, Carrión RM, López-Muñiz JI, Novoa SA, Rodríguez AL, Fidalgo JA, Lozano JF, Gasión OB, Carrascal EC, Capilla AH, López-Barajas IB, Mateu MM, de Ceballos Reyna MH, Ferrando AO, Jañez NM, Ballerini VC, Torres AA, Catalán G, Sáenz JA, Menjón S, González-Angulo AM.

Breast Cancer Res Treat. 2014 Feb;143(3):507-15. doi: 10.1007/s10549-013-2825-2. Epub 2014 Jan 11.

20.

[Changing behavior of estrogen and progesterone receptors with metastasis or recurrence of breast cancer].

Morimoto K, Koh M, Yamamoto A, Tamura K, Yamamoto K, Yamamoto K, Suehiro S.

Gan To Kagaku Ryoho. 2006 Jul;33(7):925-9. Japanese.

PMID:
16835481

Supplemental Content

Support Center